Is active targeting of brain metastases of breast cancer superior to passive targeting?

Abstract

Brain metastasis is a major cause of death in patients with solid cancers. Breast cancer cells have high tendency to migrate towards brain. Cancer cells within brain are characterized by severe aggressiveness and inaccessibility. Currently, breast cancer and its metastasis are the second leading cause of death among women. Tumor microenvironment and blood brain barrier (BBB) represent great obstacles in targeting breast cancer and its metastasis. Chemotherapy is a safer treatment modality for brain metastasis compared with risky surgical resection and brain radiotherapy. Unfortunately, conventional chemotherapy lack penetration of BBB and suffer from multiple resistance mechanisms. Current treatment technologies for brain metastases of breast cancer have limited long-term success and numerous side effects, illustrating the urgent need for novel smart strategies. Various novel drug entities and nanosystems have been employed to improve diagnosis and targeted treatment of breast cancer and its metastasis. Immunotherapy agents and small tyrosine kinase inhibitors have been shown to reduce tumor size and increase survival in patients with breast cancer, but still poorly penetrate BBB. Tailored sized nanoparticles to some extent crossed brain tumor barrier and enhanced drug accumulation in tumors by taking advantage of enhanced permeability and retention. Furthermore, various active targeting strategies have been adopted to improve accessibility to brain malignancies. Therefore, to achieve enhanced antitumor therapy against breast cancer and its brain metastasis, multi-talented delivery systems are urgently needed for optimal treatment. This review focuses on the various active and passive targeting technologies for the treatment of breast cancer brain metastases in the past decade. A comprehensive summary and examples along with pros and cons of each system will be discussed. Different treatment modalities and nanotechnology facilities will be demonstrated to aid in designing the optimal smart, safe, targeted and effective systems to combat brain metastases of breast cancer.

Keywords

Active targeting / passive targeting / brain metastasis / breast cancer

References

[1] Lin NU.Breast cancer brain metastases: new directions in systemic therapy..ecancermedicalscience2013;7:307 PMCID:PMC3646423

[2] Palmieri D,Lockman PR,Gril B.Brain metastases of breast cancer..Breast Dis2006;26:139-47

[3] Yeh RH,Chu CH,Kao HW.Distinct MR imaging features of triple-negative breast cancer with brain metastasis..J Neuroimaging2015;25:474-81

[4] Steeg PS,Smith QR.Brain metastases as preventive and therapeutic targets..Nat Rev Cancer2011;11:352-63

[5] Lin NU,Sohl J,Arnaout A.Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases..Cancer2008;113:2638-45 PMCID:PMC2835546

[6] Aversa C,Geuna E,Milani A.Metastatic breast cancer subtypes and central nervous system metastases..Breast2014;23:623-8

[7] Clayton AJ,Jolly S,Burt PA.Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer..Br J Cancer2004;91:639-43 PMCID:PMC2364775

[8] Witzel I,Pantel K,Wikman H.Breast cancer brain metastases: biology and new clinical perspectives..Breast Cancer Res2016;18:8 PMCID:PMC4717619

[9] Lin X.Treatment of brain metastases..J Clin Oncol2015;33:3475-84 PMCID:PMC5087313

[10] Kotecki N,Devriendt D.Therapy of breast cancer brain metastases: challenges, emerging treatments and perspectives..Ther Adv Med Oncol2018;10:1758835918780312 PMCID:PMC6024336

[11] Adkins CE,Terrell-Hall TB,Shah N.Characterization of passive permeability at the blood-tumor barrier in five preclinical models of brain metastases of breast cancer..Clin Exp Metastasis2016;33:373-83 PMCID:PMC4804888

[12] O'Sullivan CC,Abraham J.Current challenges in the management of breast cancer brain metastases..Semin Oncol2017;44:85-100

[13] Ballabh P,Nedergaard M.The blood-brain barrier: an overview: structure, regulation, and clinical implications..Neurobiol Dis2004;16:1-13

[14] Cook LJ.Brain tumors.2011;New YorkThe Rosen Publishing Group

[15] Dauchy S,Couraud PO,Weksler B.Expression and transcriptional regulation of ABC transporters and cytochromes P450 in hCMEC/D3 human cerebral microvascular endothelial cells..Biochem Pharmacol2009;77:897-909

[16] Abbott NJ,Dolman DE,Begley DJ.Structure and function of the blood-brain barrier..Neurobiol Dis2010;37:13-25

[17] Van Tellingen O,De Gooijer MC,Wurdinger T.Overcoming the blood-brain tumor barrier for effective glioblastoma treatment..Drug Resist Updat2015;19:1-12

[18] Dong X.Current strategies for brain drug delivery..Theranostics2018;8:1481-93 PMCID:PMC5858162

[19] Rip J,de Boer AG.Differential receptor-mediated drug targeting to the diseased brain..Expert Opin Drug Deliv2009;6:227-37

[20] Abbott NJ.Overview and introduction: The blood-brain barrier in health and disease..Epilepsia2012;53:1-6 PMCID:PMC3625728

[21] Banks WA.From blood-brain barrier to blood-brain interface: new opportunities for CNS drug delivery..Nat Rev Drug Discov2016;15:275-92

[22] Anderson A,Neman J,Jandial R.Metastatic breast cancer to the brain: a clinical primer for translational investigation. Madame Curie Bioscience Database [Internet].2013;Austin (TX)Landes Bioscience

[23] Weber GF.Molecular mechanisms of metastasis..Cancer Lett2008;270:181-90

[24] Banys-Paluchowski M,Meier-Stiegen F.Circulating tumor cells in breast cancer - current status and perspectives..Crit Rev Oncol Hematol2016;97:22-9

[25] Prieto-Vila M,Usuba W,Ochiya T.Drug resistance driven by cancer stem cells and their niche..Int J Mol Sci2017;18:E2574 PMCID:PMC5751177

[26] Rahmathulla G,Weil RJ.The molecular biology of brain metastasis..J Oncol2012;2012:723541 PMCID:PMC3317231

[27] Seoane J.Brain metastasis: new opportunities to tackle therapeutic resistance..Mol Oncol2014;8:1120-31 PMCID:PMC5528619

[28] Jin X.Targeting breast cancer metastasis..Breast Cancer (Auckl)2015;9:23-34 PMCID:PMC4559199

[29] Bos PD,Nadal C,Gomis RR.Genes that mediate breast cancer metastasis to the brain..Nature2009;459:1005-9 PMCID:PMC2698953

[30] Leek RD,Lewis CE.Cytokine networks in solid human tumors: regulation of angiogenesis..J Leukoc Biol1994;56:423-35

[31] Cheng X.Breast cancer brain metastases..Cancer Metastasis Rev2007;26:635-43

[32] Lee BC,Avraham S.Involvement of the chemokine receptor CXCR4 and its ligand stromal cell-derived factor 1alpha in breast cancer cell migration through human brain microvascular endothelial cells..Mol Cancer Res2004;2:327-38

[33] Avraham HK,Fu Y,Ovadia H.Angiopoietin-2 mediates blood-brain barrier impairment and colonization of triple-negative breast cancer cells in brain..J Pathol2014;232:369-81

[34] Ahmad SA,Jung YD,Wilson M.The effects of angiopoietin-1 and -2 on tumor growth and angiogenesis in human colon cancer..Cancer Res2001;61:1255-9

[35] Valiente M,Jin X,Zhang XHF.Serpins promote cancer cell survival and vascular co-option in brain metastasis..Cell2014;156:1002-16 PMCID:PMC3988473

[36] Becker A,Weiss JM,Peinado H.Extracellular vesicles in cancer: cell-to-cell mediators of metastasis..Cancer cell2016;30:836-48 PMCID:PMC5157696

[37] Lin NU,Winer EP.CNS metastases in breast cancer..J Clin Oncol2004;22:3608-17

[38] Lockman PR,Taskar KS,Gril B.Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer..Clin Cancer Res2010;16:5664-78 PMCID:PMC2999649

[39] Villanueva MT.Drug therapy: smuggling trastuzumab into the brain..Nat Rev Clin Oncol2013;10:669

[40] Yonemori K,Ono M,Hirakawa A.Disruption of the blood brain barrier by brain metastases of triple-negative and basal-type breast cancer but not HER2/neu-positive breast cancer..Cancer2010;116:302-8

[41] Brosnan EM.Understanding patterns of brain metastasis in breast cancer and designing rational therapeutic strategies..Ann Transl Med2018;6:163 PMCID:PMC5985267

[42] ELAmrawy F,Adkins C,Nounou MI.Tailored nanocarriers and bioconjugates for combating glioblastoma and other brain tumors..J Cancer Metastasis Treat2016;2:112-22

[43] Kazantsev AG.Drug discovery for CNS disorders: from bench to bedside..CNS Neurol Disord Drug Targets2010;9:668

[44] Gabathuler R.Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases..Neurobiol Dis2010;37:48-57

[45] Pardridge WM.Drug delivery to the brain..J Cereb Blood Flow Metab1997;17:713-31

[46] Barar J,Pourseif MM.Blood-brain barrier transport machineries and targeted therapy of brain diseases..BioImpacts2016;6:225-48 PMCID:PMC5326671

[47] Dhankhar R,Jain AK,Rath G.Advances in novel drug delivery strategies for breast cancer therapy..Artif Cells Blood Substit Immobil Biotechnol2010;38:230-49

[48] Matsumura Y.A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs..Cancer Res1986;46:6387-92

[49] Kobayashi H,Watanabe R.Cancer drug delivery: considerations in the rational design of nanosized bioconjugates..Bioconjug Chem2014;25:2093-100 PMCID:PMC4275162

[50] Singh R.Nanoparticle-based targeted drug delivery..Experimental and molecular pathology2009;86:215-23 PMCID:PMC3249419

[51] Blanco E,Ferrari M.Principles of nanoparticle design for overcoming biological barriers to drug delivery..Nat Biotechnol2015;33:941-51 PMCID:PMC4978509

[52] Liechty WB.Expert opinion: responsive polymer nanoparticles in cancer therapy..Eur J Pharm Biopharm2012;80:241-6 PMCID:PMC3269567

[53] Davis ME,Shin DM.Nanoparticle therapeutics: an emerging treatment modality for cancer..Nat Rev Drug Discov2008;7:771-82

[54] Lammers T,Hennink WE.Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress..J Control Release2012;161:175-87

[55] Din FU,Ullah I,Mustapha O.Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors..Int J Nanomedicine2017;12:7291-309 PMCID:PMC5634382

[56] Weissenbock A,Gabor F.WGA-grafted PLGA-nanospheres: preparation and association with Caco-2 single cells..J Control Release2004;99:383-92

[57] Wesselinova D.Current major cancer targets for nanoparticle systems..Curr Cancer Drug Targets2011;11:164-83

[58] De Jong WH.Drug delivery and nanoparticles:applications and hazards..Int J Nanomedicine2008;3:133-49 PMCID:PMC2527668

[59] Perche F.Recent trends in multifunctional liposomal nanocarriers for enhanced tumor targeting..J Drug Deliv2013;2013:705265 PMCID:PMC3606784

[60] Mohammad AS,Adkins CE,Sechrest E.Liposomal irinotecan accumulates in metastatic lesions, crosses the blood-tumor barrier (BTB), and prolongs survival in an experimental model of brain metastases of triple negative breast cancer..Pharm Res2018;35:31 PMCID:PMC5884086

[61] Hamidi M,Rafiei P.Pharmacokinetic consequences of pegylation..Drug Delivery2006;13:399-409

[62] Salmaso S.Stealth properties to improve therapeutic efficacy of drug nanocarriers..J Drug Deliv2013;2013:374252 PMCID:PMC3606770

[63] Vail DM,Colbern GT,Hilger RA.Pegylated liposomal doxorubicin: proof of principle using preclinical animal models and pharmacokinetic studies..Semin Oncol2004;31:16-35

[64] Yokoyama M,Yamada N,Sakurai Y.Characterization and anticancer activity of the micelle-forming polymeric anticancer drug adriamycin-conjugated poly(ethylene glycol)-poly(aspartic acid) block copolymer..Cancer Res1990;50:1693-700

[65] James ND,Tomlinson D,Gompels M.Liposomal doxorubicin (Doxil): an effective new treatment for Kaposi's sarcoma in AIDS..Clin Oncol (R Coll Radiol)1994;6:294-6

[66] Muggia FM.Doxil in breast cancer..J Clin Oncol1998;16:811-2

[67] Porche DJ.Liposomal doxorubicin (Doxil)..J Assoc Nurses AIDS Care1996;7:55-9

[68] Anders CK,Karginova O,Rawal S.Pharmacokinetics and efficacy of PEGylated liposomal doxorubicin in an intracranial model of breast cancer..PLoS One2013;8:e61359 PMCID:PMC3641071

[69] Zhao X,Ren Z.Therapeutics N.Multi-arm polymer prodrugs..The United States Patent and Trademark Office.2013;USNektar Therapeutics

[70] Zhang W.Method for preparing a polymer conjugate.2013;USANektar therapeutics

[71] Minamitani EL,Bossard MJ,Liu X.Polymer conjugates of kiss1 peptides.2011;USANektar therapeutics

[72] Hoch U,Leung ACF.Therapeutics N.Treatment of patients suffering from cancer..The United States Patent and Trademark Office.2013;USNektar Therapeutics

[73] Fishburn CS,Viegas T,Song Y.Therapeutics N.Chemically modified small molecules..The United States Patent and Trademark Office.2011;USNektar Therapeutics

[74] Eldon MA,Barker TL.Therapeutics N.Compositions and methods for achieving sustained therapeutic drug concentrations in a subject..The United States Patent and Trademark Office.2011;USNektar Therapeutics

[75] Chen YC,Chen LF,Hsieh WY.Polymersomes conjugated with des-octanoyl ghrelin and folate as a BBB-penetrating cancer cell-targeting delivery system..Biomaterials2014;35:4066-81

[76] Adkins CE,Hye T,Terrell-Hall T.NKTR-102 Efficacy versus irinotecan in a mouse model of brain metastases of breast cancer..BMC Cancer2015;15:685 PMCID:PMC4604629

[77] Gaillard PJ.2-BBB Products’ Pipline.2018;Leiden Bio Science Park, The Netherlands2-BBB Medicines BV

[78] Geldenhuys W,Groshev A,Sutariya V.Brain-targeted delivery of doxorubicin using glutathione-coated nanoparticles for brain cancers..Pharm Dev Technol2015;20:497-506

[79] Kanasty R,Vegas A.Delivery materials for siRNA therapeutics..Nat Mater2013;12:967-77

[80] Wang G,Xu X,Zhang R.Novel miR-122 delivery system based on MS2 virus like particle surface displaying cell-penetrating peptide TAT for hepatocellular carcinoma..Oncotarget2016;7:59402-16 PMCID:PMC5312320

[81] Zhang L,Goodman JC,Marchetti D.MicroRNA-1258 suppresses breast cancer brain metastasis by targeting heparanase..Cancer Res2011;71:645-54 PMCID:PMC3078691

[82] Rodriguez-Devora JI,Shi Z-D,Sun W.Physically facilitating drug-delivery systems..Therapeutic delivery2012;3:125-39 PMCID:PMC3319129

[83] Davalos RV,Garcia PA.Acute blood-brain barrier disruption using electrical energy based therapy.2014;Virginia Tech Intellectual Properties, Inc.

[84] Park EJ,Vykhodtseva N.Ultrasound-mediated blood-brain/blood-tumor barrier disruption improves outcomes with trastuzumab in a breast cancer brain metastasis model..J Control Release2012;163:277-84 PMCID:PMC3502612

[85] Kobus T,Zhang Y.Growth inhibition in a brain metastasis model by antibody delivery using focused ultrasound-mediated blood-brain barrier disruption..J Control Release2016;238:281-8 PMCID:PMC5014601

[86] Kinoshita M,Jolesz FA.Noninvasive localized delivery of Herceptin to the mouse brain by MRI-guided focused ultrasound-induced blood-brain barrier disruption..Proceedings of the National Academy of Sciences2006;103:11719-23 PMCID:PMC1544236

[87] Kinoshita M,Jolesz FA.Noninvasive localized delivery of Herceptin to the mouse brain by MRI-guided focused ultrasound-induced blood-brain barrier disruption..Proc Natl Acad Sci U S A2006;103:11719-23 PMCID:PMC1544236

[88] Nobs L,Gurny R.Poly(lactic acid) nanoparticles labeled with biologically active Neutravidin for active targeting..Eur J Pharm Biopharm2004;58:483-90

[89] Prinzen L,Dirksen A,Deckers N.Optical and magnetic resonance imaging of cell death and platelet activation using annexin a5-functionalized quantum dots..Nano Lett2007;7:93-100

[90] Wang YY,Li JY.Receptor-mediated therapeutic transport across the blood-brain barrier..Immunotherapy2009;1:983-93

[91] Jones AR.Blood-brain barrier transport of therapeutics via receptor-mediation..Pharm Res2007;24:1759-71 PMCID:PMC2685177

[92] Lin NU.Targeted therapies in brain metastases..Curr Treat Options Neurol2014;16:276 PMCID:PMC3895218

[93] Beliveau R.Method for transporting a compound across the blood-brain barrier.2003;AngioChem Inc.

[94] Regina A,Che C,Poirier J.Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2..Br J Pharmacol2008;155:185-97 PMCID:PMC2538693

[95] Regina A,Tripathy S,Currie JC.ANG4043, a novel brain-penetrant peptide-mAb conjugate, is efficacious against HER2-positive intracranial tumors in mice..Mol Cancer Ther2015;14:129-40

[96] Thomas FC,Rudraraju V,Thorsheim HR.Uptake of ANG1005, a novel paclitaxel derivative, through the blood-brain barrier into brain and experimental brain metastases of breast cancer..Pharm Res2009;26:2486-94 PMCID:PMC2896053

[97] Orthmann A,Suss R,Lemm M.Treatment of experimental brain metastasis with MTO-liposomes: impact of fluidity and LRP-targeting on the therapeutic result..Pharm Res2012;29:1949-59

[98] Orthmann A,Fichtner I,Hilger RA.Improved treatment of MT-3 breast cancer and brain metastases in a mouse xenograft by LRP-targeted oxaliplatin liposomes..J Biomed Nanotechnol2016;12:56-68

[99] Demeule M,Jodoin J,Desrosiers RR.High transcytosis of melanotransferrin (P97) across the blood-brain barrier..J Neurochem2002;83:924-33

[100] Dorries R.The role of T-cell-mediated mechanisms in virus infections of the nervous system..Curr Top Microbiol Immunol2001;253:219-45

[101] Nounou MI,Rubinchik E,Afroz M.Anti-cancer antibody trastuzumab-melanotransferrin conjugate (BT2111) for the treatment of metastatic HER2+ breast cancer tumors in the brain: an in-vivo study..Pharm Res2016;33:2930-42 PMCID:PMC5267937

[102] Ruoslahti E.Tumor penetrating peptides for improved drug delivery..Advanced Drug Delivery Reviews2017;110-111:3-12 PMCID:PMC5045823

[103] Teesalu T,Ruoslahti E.Tumor-penetrating peptides..Front Oncol2013;3:216 PMCID:PMC3753659

[104] Hamilton AM,Sharma S,Foster PJ.Nanoparticles coated with the tumor-penetrating peptide iRGD reduce experimental breast cancer metastasis in the brain..J Mol Med (Berl)2015;93:991-1001 PMCID:PMC4807972

[105] Pardridge WM.Blood-brain barrier carrier-mediated transport and brain metabolism of amino acids..Neurochem Res1998;23:635-44

[106] Tsuji A.Small molecular drug transfer across the blood-brain barrier via carrier-mediated transport systems..NeuroRx2005;2:54-62 PMCID:PMC539320

[107] Chiou B,Bowman AB,Simpson IA.Pharmaceutical iron formulations do not cross a model of the human blood-brain barrier..PloS One2018;13:e0198775 PMCID:PMC5995392

[108] Lameijer MA,Nahrendorf M,Mulder WJM.Monocytes and macrophages as nanomedicinal targets for improved diagnosis and treatment of disease..Expert Rev Mol Diagn2013;13:567-80 PMCID:PMC4110962

[109] Choi M-R,Stanton-Maxey KJ,Nakshatri H.Delivery of nanoparticles to brain metastases of breast cancer using a cellular Trojan horse..Cancer nanotechnol2012;3:47-54 PMCID:PMC3505533

[110] Stalmans S,Wynendaele E,Peremans K.Cell-penetrating peptides selectively cross the blood-brain barrier in vivo..PLoS One2015;10:e0139652 PMCID:PMC4605843

[111] Mae M.Cell-penetrating peptides as vectors for peptide, protein and oligonucleotide delivery..Curr Opin Pharmacol2006;6:509-14

[112] Morshed RA,Dai Q,Auffinger B.Cell-penetrating peptide-modified gold nanoparticles for the delivery of doxorubicin to brain metastatic breast cancer..Mol Pharm2016;13:1843-54

[113] Fu B,Zhang Y,Miao F.Enhanced antitumor effects of the BRBP1 compound peptide BRBP1-TAT-KLA on human brain metastatic breast cancer..Sci Rep2015;5:8029 PMCID:PMC4306141

[114] Meyers JD,Burda C.Nanoparticles for imaging and treating brain cancer..Nanomedicine (Lond)2013;8:123-43 PMCID:PMC3564670

[115] Kunjachan S,Gremse F,Ehling J.Passive versus active tumor targeting using RGD- and NGR-modified polymeric nanomedicines..Nano Lett2014;14:972-81 PMCID:PMC3940962

[116] Golombek SK,Theek B,Drude N.Tumor targeting via EPR: strategies to enhance patient responses..Adv Drug Deliv Rev2018;130:17-38 PMCID:PMC6130746

[117] Baetke SC,Kiessling F.Applications of nanoparticles for diagnosis and therapy of cancer..Br J Radiol2015;88:20150207 PMCID:PMC4630860

[118] Kiessling F,Grimm J.Nanoparticles for imaging: top or flop?.Radiology2014;273:10-28 PMCID:PMC4186876

[119] Kunjachan S,Storm G,Lammers T.Multidrug resistance: physiological principles and nanomedical solutions..Adv Drug Deliv Rev2013;65:1852-65 PMCID:PMC3939439

[120] Lammers T,Storm G.Personalized nanomedicine..Clin Cancer Res2012;18:4889-94

[121] Devarajan PV,Patil RR,Gaikwad RV.Particle shape: a new design parameter for passive targeting in splenotropic drug delivery..J Pharm Sci2010;99:2576-81

[122] Lammers T,Storm G.Tumour-targeted nanomedicines: principles and practice..Br J Cancer2008;99:392-7 PMCID:PMC2527811

[123] Rosenblum D,Tao W,Peer D.Progress and challenges towards targeted delivery of cancer therapeutics..Nat Commun2018;9:1410 PMCID:PMC5897557

[124] Siegrist S,Detampel P,Wick P.Preclinical hazard evaluation strategy for nanomedicines..Nanotoxicology2018;1-27